What Happened?
Port Hueneme, CA-based Stellar Biotechnologies has announced the Resignation of Herbert S. Chow as Chief Technology Officer
About the Company
Stellar Biotechnologies is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimers, and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.
About the Person
Herbert S. Chow, also known as Herb, Ph.D. has been the Chief Technology Officer of Stellar Biotechnologies, Inc. since August 9, 2012. Dr. Chow served as a Vice President of Product Development at Stellar Biotechnologies, Inc. from May 2010 to August 9, 2012. Dr. Chow held key business management and product development positions in new biologic devices, clinical diagnostic and consumer diagnostic markets. He has considerable operational expertise in developing and commercializing innovative technologies, and building successful strategic partnership in the fields of medical diagnostic and therapeutic devices. Previously, he held key senior management positions with start-up biotechnology companies, as well as international pharmaceutical companies Abbott Labs and Johnson & Johnson. In more than 25 years in the life sciences, Dr. Chow has been granted nine patents in chemical processing, microfluidic devices, liquid sensing devices and medical devices for point-of-care diagnosis. He earned his BS in Microbiology and Immunochemistry at Ohio State University and his Ph.D. in Immunopathology at the University of Illinois.
Info Source
News
Short Profile